期刊文献+

胃肠间质瘤及其转化医学 被引量:5

Gastrointestinal stromal tumors and translational medicine
原文传递
导出
摘要 胃肠间质瘤是近年重新认识并且在治疗上取得较大突破的实体肿瘤类型。从发现其主要的发病机制开始,不久即出现了针对性的治疗药物,成为最早进入"靶向治疗"的肿瘤类型之一,体现了转化医学倡导的从实验室研究成果到临床应用的快速转化。回顾10余年来对该病的认识与诊治过程,本身就是对于肿瘤转化医学这一新兴的医学研究模式极佳的诠释。 Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. Gain-of-function mutations on tyrosine kinase receptor are the keys of oncogenesis in GIST, which become the target of therapy, as well as the mechanism of drug resistance. A decade of progress in clinical management of GIST becomes a model of translational medicine research, which advocates rapid conversion from the laboratory achievement to clinical application.
出处 《中国实用外科杂志》 CSCD 北大核心 2012年第1期36-39,共4页 Chinese Journal of Practical Surgery
关键词 胃肠间质瘤 转化医学 基因突变 靶向治疗 gastrointestinal stromal tumor translational medi-cine gene mutation targeted therapy
  • 相关文献

参考文献30

  • 1Miettinen M. Sarcoma and gastrointestinal stromal tumors. In: Jankowski J, Sampliner R, Kerr D, et al. Gastrointestinal oncolo- gy: A critical muhidisciplinat.'y team approach [M]. Massachu- setts : Blackwell publishing, 2008: 227-258.
  • 2Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function muta- tions of c-kit in human gastrointestinal stromal tumors [J]. Sci- ence, 1998, 279(5350):577-580.
  • 3Heinrich MC, Corless CL, Duensing A, el al. PDGFRA activat- ing mutations in gaslrointestinal stromal tumors [J]. Science, 2003, 299 (5607):708-710.
  • 4Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastroin- testinal stromal tumors: a consensus approach [J]. Hum Pathol, 2002, 33(5):459-465.
  • 5Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential di- agnosis [J]. Arch Pathol Lab ged, 2006, 130(10):1466-1478.
  • 6DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointes- tinal stromal tumors: recurrence patterns and prognostic factors for survival [J]. Ann Surg, 2000, 231(1):251-258.
  • 7Tuveson DA, Willis NA, Jacks T, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical'implications[J].Oncogcne 2001 20(36): 5054-5058.
  • 8Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the ty- rosine kinase inhabitor STI571 in a patient with a matastatic, gas- trointestinal stromal tumor [J]. N Eng J Med, 2001, 344(14) 1052-1056.
  • 9Demetri GD, yon Mehren M, Blande CD, et al. efficacy and safe- ty of imatinih mesylate in advanced gastrointestinal stromal tumors[J]. N Eng J Med, 2002, 347(7), 472-480.
  • 10Verweij J, van Oosterom A, Blay JY, et al. hnatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tis- sue sarcomas that are unseleeted for a molecular target. Results from an EOBTC Soft Tissue and Bone Sarcoma Group phase Ⅱ study[J]. Eur J Cancer, 2003,39(14):2006-2011.

二级参考文献21

  • 1Mudan SS,Conlon KC,Woodruff J,et al.Salvage surgery in recurrent gastrointestinal sarcoma:prognostic factors to guide patient selection.Cancer,2000,88:66-74.
  • 2DeMatteo RP,Lewis JJ,Leung D,et al.Two hundred gastrointestinal stromal tumors:recurrence patterns and prognostic factors for survival.Ann Surg,2000,231:51-58.
  • 3Mocellin S,Mencarelli R,Foletto M,et al.Gastrointestinal stromal tumors:from a surgical to a molecular approach.Int J Cancer,2003,107:171-176.
  • 4Dematteo RP,Shah A,Fong Y,et al.Results of hepatic resection for sarcoma metastatic to liver.Ann Surg,2001,234:540-548.
  • 5Husted TL,Neff G,Thomas MJ,et al.Liver transplantation for primary or metastatic sarcoma to the liver.Am J Transplant,2006,6:392-397.
  • 6Blanke CD,Demetri GD,Von Mehren M,et al.kong-term follow-up of a phase Ⅱ randomized trial in advanced gastrointestinal stromal tumor (GIST) patients treated with imatinib mesylate.Abstract No:9528,J Clin Oncol,2006 ASCO Annual Meeting Proceedings Part Ⅰ.Vol 24,No.18S.
  • 7Perez EA,Livingstone AS,Franceschi D,et al.Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors.J Am Coll Surg,2006,202:623-629.
  • 8Goettsch WG,Bos SD,Broekveldt-Postma N,et al.Incidence of gastrointestinal stromal tumours is underestimated:results of a nation-wide study.Eur J Cancer,2005,41:2868-2872.
  • 9Miettinen M,Lasota J.Gastrointestinal stromal tumours-definition,clinical,histological,immunohistochemical,and molecular genetic features and differential diagnosis.Virchows Arch,2001,438:1-12.
  • 10Demetri GD,von Mehren M,Blanke CD,et al.Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumours.N Engl J Med,2002,347:472-480.

共引文献84

同被引文献63

引证文献5

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部